about
Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinomaMechanical oscillations enhance gene delivery into suspended cells.Targeting SR-BI for Cancer Diagnostics, Imaging and TherapyReconsideration of in-silico siRNA design based on feature selection: a cross-platform data integration perspectiveA retro-inverso cell-penetrating peptide for siRNA delivery.Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.Functional delivery of siRNA in mice using dendriworms.Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis via mitochondrial pathway.PSMA-targeted theranostic nanoplex for prostate cancer therapy.Post-transcriptional processing of genetic information and its relation to cancer.Exploiting cancer genomics in pet animals to gain advantage for personalized medicine decisions.Down regulation of BCL11B expression inhibits proliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA.Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.Downregulation of survivin by siRNA inhibits invasion and promotes apoptosis in neuroblastoma SH-SY5Y cells.Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapyAnalysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemiaGene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNATargeting of the β6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells.Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapyNanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells.Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation.Targeting fungal genes by diced siRNAs: a rapid tool to decipher gene function in Aspergillus nidulansDownregulation of Kinesin spindle protein inhibits proliferation, induces apoptosis and increases chemosensitivity in hepatocellular carcinoma cells.Human cytomegalovirus replication is strictly inhibited by siRNAs targeting UL54, UL97 or UL122/123 gene transcriptsDownregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells.Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions.An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastomasiRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo.Beyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles.ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast CancerTargeted polymeric nanoparticles for cancer gene therapy.MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitroEffects of down-regulation of clusterin by small interference RNA on human acute myeloid leukemia cells.Delivery of intracellular-acting biologics in pro-apoptotic therapies.The potential for phospholipase D as a new therapeutic target.RNA as a versatile and powerful platform for engineering genetic regulatory tools.
P2860
Q26823523-7E046290-D90D-4924-9715-1E0E4CFFB42EQ27333643-1DCCA8B9-E5D1-4CD3-8237-B4B1F235B817Q28066708-7610FE3E-9115-4354-A1DB-CE7EEE1899C8Q28483920-450F6A6D-C0D9-4028-A87A-F12BF7F16CD6Q30847307-75614551-BDDE-4C93-8C77-31BCA2F27CBBQ30854643-DC29999A-56D5-40EE-84C2-BEBBAF07C7B1Q33686651-4AE6B6F3-9525-4E0C-A73F-2E914E9C8010Q33754728-18DB840F-DDFB-4D02-ACCE-8EE79C2E8BDCQ33791366-A722712C-F509-40B4-A196-C7672D32D59EQ33881478-6504E100-43F0-4382-A784-F7A3F1CDEEF4Q33917501-798CEFF7-7D55-4ED6-9B0F-FA9FE0F5E03CQ33960952-B7D75907-304D-41CA-85AF-7BF524F58DAAQ33991008-38493364-7E40-49D6-9BB1-A651A2056601Q34010661-D9E215FE-AA6E-4385-B393-D9CA43785EDAQ34348175-1E45784C-5E5B-4546-A44B-788CEC3BAF7EQ34353401-7C9971B9-6B25-47CC-84DF-B411B0A9ADE1Q34365466-33B9ED86-2C95-45A1-9A71-800B5E45FC0CQ34372155-A7681038-FCB8-49DD-9D1A-D56432134578Q34550420-11DE30A2-A0A6-4E08-AD29-13F19E318283Q34616158-6F0A76B2-17E6-4734-9B62-8916B4A85CB7Q34622662-7D1A4DF4-E090-4CB4-86E3-1A9A6141F903Q34727214-84C3655B-2EA1-4EFD-A9F8-44F66AC25530Q34900837-DB256211-8624-4D9B-974A-52C5FD02173BQ34978247-11EC49E3-1527-4F6B-B002-730C9ECF7D3BQ35018283-16C54360-7576-4C64-8FFF-661410DA90FEQ35065391-6D272B09-5DAF-478B-A49A-2B2084187650Q35179708-35966FE6-805D-4891-823A-1A6388C1D1DEQ35856029-3F8B8F7F-4CA0-42AB-AF44-0665459C4FCBQ35924301-C7FDC16E-1305-454A-B275-2738C7E95D4EQ35943427-66D363D5-702B-477C-9846-C012E6C91A5BQ36093931-F7873660-0692-4AFE-A397-550E9089D13FQ36244123-FAB23234-3976-4605-972B-8B706AC3322EQ36247616-406975C8-557D-40E2-9D52-0E67C25CE74BQ36372319-AC4FD632-C884-4C5C-9F14-45C0FC3DADDFQ36416427-FF23EBCB-B721-42E1-927F-7474764240D2Q36426830-4E971391-88A8-41DA-AB2B-9A18DCF27B6FQ36492908-587BAAE2-A72A-4374-A4AF-2ADB549154CDQ36588920-C004F22D-1A77-4E98-B4A0-3D060DD04920Q36804452-B23D50C1-7C3D-470B-AF5C-C08217E729BAQ37024725-B7F64C7E-B432-4B8E-8C38-504CEB723BF8
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
siRNA-based approaches in cancer therapy.
@ast
siRNA-based approaches in cancer therapy.
@en
type
label
siRNA-based approaches in cancer therapy.
@ast
siRNA-based approaches in cancer therapy.
@en
prefLabel
siRNA-based approaches in cancer therapy.
@ast
siRNA-based approaches in cancer therapy.
@en
P356
P1433
P1476
siRNA-based approaches in cancer therapy.
@en
P2093
P2888
P304
P356
10.1038/SJ.CGT.7700931
P577
2006-01-20T00:00:00Z